{"title":"1例重症肌无力青年患者的COVID-19与心脏性猝死","authors":"Maysa Ghayyem, S. Haseli, S. Yaghmaei","doi":"10.30654/mjcr.10068","DOIUrl":null,"url":null,"abstract":"Myasthenic patients are expected to develop more severe COVID-19 respiratory symptoms compared to the general population because of both respiratory muscle weakness and the possibility of an immunocompromised state related to immunotherapy. During a pandemic like COVID-19, such situation requires meticulous attention, as the entire population is potentially at risk of exposure. However, there is no data on best management for myasthenic patients with COVID infection.","PeriodicalId":92691,"journal":{"name":"Mathews journal of case reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 and Sudden Cardiac Death in a Young Man with Myasthenia Gravis\",\"authors\":\"Maysa Ghayyem, S. Haseli, S. Yaghmaei\",\"doi\":\"10.30654/mjcr.10068\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Myasthenic patients are expected to develop more severe COVID-19 respiratory symptoms compared to the general population because of both respiratory muscle weakness and the possibility of an immunocompromised state related to immunotherapy. During a pandemic like COVID-19, such situation requires meticulous attention, as the entire population is potentially at risk of exposure. However, there is no data on best management for myasthenic patients with COVID infection.\",\"PeriodicalId\":92691,\"journal\":{\"name\":\"Mathews journal of case reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mathews journal of case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30654/mjcr.10068\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mathews journal of case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30654/mjcr.10068","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
COVID-19 and Sudden Cardiac Death in a Young Man with Myasthenia Gravis
Myasthenic patients are expected to develop more severe COVID-19 respiratory symptoms compared to the general population because of both respiratory muscle weakness and the possibility of an immunocompromised state related to immunotherapy. During a pandemic like COVID-19, such situation requires meticulous attention, as the entire population is potentially at risk of exposure. However, there is no data on best management for myasthenic patients with COVID infection.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
